GET DAILY SIGNALSClarivate (CLVT) Shares Advance +35.8% After Divestiture and Earnings Beat
Key Takeaways
- Clarivate shares rose roughly 35.8% over the past 30 days, climbing from about $1.48 to near $2.01, a rebound from a 52-week low set in early October.
- The rally was driven by the completed $600 million sale of its Life Sciences & Healthcare segment, an earnings beat, and accelerating AI-related product momentum.
- Third-quarter adjusted diluted EPS of $0.21 topped the $0.18 consensus, while Intellectual Property annual contract value returned to growth for the first time in over three years.
- The stock's three-month trend remains volatile: shares slid from roughly $1.94 in early August to about $1.42–$1.45 in early October before the sharp recovery.
- Key risks include continued pressure on transactional revenue, a trimmed full-year growth outlook, and a still-elevated net debt load of roughly $4.2 billion.
- For deeper data on this ticker, explore Price Targets, Earnings, and Forecast pages.
Clarivate (CLVT) Business Overview
CLVT is a London-headquartered provider of transformative intelligence, offering enriched data, analytics, workflow software, and expert services through two main segments: Academia & Government and Intellectual Property. Its established platforms include Web of Science, ProQuest, Derwent, CompuMark, and the IPfolio and Alma solutions. The company works with universities, research institutions, libraries, governments, and IP-focused enterprises, generating about 93% of revenue from recurring sources. After selling its Life Sciences & Healthcare business, CLVT operates as a more focused subscription-oriented company with roughly $2 billion in annual revenue.
Recent Stock Performance Over 30 Days and the Quarter
Over the last 30 days, CLVT shares advanced roughly 35.8%, moving from a closing price near $1.48 in early October to about $2.01. The move followed a sharp rally that accelerated on the day of the third-quarter earnings release in early November. The three-month view shows more volatility, with the stock starting the period near $1.94 before declining through September amid leverage concerns and softer growth expectations, reaching the $1.42–$1.45 area in early October near the low end of its 52-week range of roughly $1.42 to $3.87. The rebound left shares up only about 4% for the full quarter.
Factors Behind the Recent 30-Day Rally
Multiple developments supported the advance. On October 6, CLVT completed the $600 million sale of its Life Sciences & Healthcare segment to Altaris, LLC, streamlining operations and directing proceeds toward debt reduction. The third-quarter results released in early November provided the strongest catalyst, with adjusted diluted EPS of $0.21 beating the $0.18 consensus. Management noted that Intellectual Property annual contract value turned positive for the first time in more than three years. Recurring organic revenue grew 1.3%, the best pace in over a year, and adjusted EBITDA margin expanded to 45.3% from 41.9% a year earlier. AI initiatives also helped sentiment, as the Web of Science Research Intelligence platform surpassed 100 institutional wins across 25 countries and the IPOne agentic-AI platform built an active pipeline of more than 150 customers. A partnership with Sterne Kessler to develop AI-enhanced patent tools added further support. I also checked this using Tickeron’s AI Trend Prediction Engine to gauge momentum signals.
Quarterly Context and Transition Pressures
The broader quarterly picture reflects a company navigating change. Through August and September, pressure came from a sizable debt load, the wind-down of lower-margin activities, and tempered organic-growth expectations. The Life Sciences & Healthcare divestiture, announced in July and closed ahead of schedule in October, stood out as the key strategic move. As the transaction wrapped and recurring-revenue metrics improved alongside AI progress and steps toward roughly $875 million in full-year debt reduction, sentiment turned more constructive. The rebound shows investors are increasingly recognizing the repositioning, even while reported revenue faces headwinds from disposals and weaker transactional volumes. From what I see, tracking these shifts remains essential.
Key Areas to Monitor Going Forward
Investors will want to watch whether CLVT sustains recurring-revenue and annual contract value momentum, especially the conversion of IPOne and Web of Science Research Intelligence pipelines into contracted revenue. Fourth-quarter and full-year guidance, including the $320 million to $340 million free-cash-flow range, will draw attention, along with debt-reduction progress and the path to a 3.5x to 3.6x net-leverage target by the end of 2027. Macro factors such as higher-education funding, foreign-exchange movements, and software-sector sentiment could also play a role. These considerations are informational and should not be treated as financial advice.
Exploring AI-Driven Trading Approaches
I’ve found Tickeron’s Trending AI Robots page useful for reviewing a focused selection of AI-driven trading bots drawn from a wider set that covers thousands of tickers. Only the top-performing and most relevant bots appear here, allowing a clearer look at strategies that align with current market conditions. The bots differ in approach, timeframe, and metrics, helping match different risk profiles and holding periods. Checking the page gives a practical sense of how algorithmic systems are positioned across the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CLVT's Indicator enters downward trend
The Aroon Indicator for CLVT entered a downward trend on October 16, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 271 similar instances where the Aroon Indicator formed such a pattern. In 225 of the 271 cases the stock moved lower. This puts the odds of a downward move at 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
CLVT broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 71 cases where CLVT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on CLVT as a result. In 50 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
The Moving Average Convergence Divergence (MACD) for CLVT just turned positive on October 13, 2026. Looking at past instances where CLVT's MACD turned positive, the stock continued to rise in 31 of 46 cases over the following month. The odds of a continued upward trend are 67%.
CLVT moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +26.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLVT advanced for three days, in 157 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.234) is normal, around the industry mean (2.796). P/E Ratio (-3.192) is within average values for comparable stocks, (18.242). Projected Growth (PEG Ratio) (0.178) is also within normal values, averaging (2.284). Dividend Yield (0.000) settles around the average of (0.207) among similar stocks. P/S Ratio (0.504) is also within normal values, averaging (139.965).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. CLVT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLVT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of activated carbon and related products and systems
Industry InformationTechnologyServices
Advertisement